Share on StockTwits

Research analysts at Stifel Nicolaus raised their price objective on shares of Salix Pharmaceuticals (NASDAQ:SLXP) from $150.00 to $155.00 in a report released on Thursday. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 15.81% from the company’s current price.

In other Salix Pharmaceuticals news, CEO Carolyn J. Logan unloaded 53,057 shares of the stock in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $123.38, for a total value of $6,546,172.66. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Several other analysts have also recently commented on the stock. Analysts at Brean Capital raised their price target on shares of Salix Pharmaceuticals from $125.00 to $150.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Mizuho raised their price target on shares of Salix Pharmaceuticals from $151.00 to $184.00 in a research note on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Piper Jaffray reiterated a “positive” rating on shares of Salix Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $127.84.

Salix Pharmaceuticals (NASDAQ:SLXP) traded up 0.41% on Thursday, hitting $133.84. 1,882,279 shares of the company’s stock traded hands. Salix Pharmaceuticals has a 52-week low of $64.93 and a 52-week high of $141.81. The stock has a 50-day moving average of $119.8 and a 200-day moving average of $107.1. The company has a market cap of $8.487 billion and a P/E ratio of 113.25.

Salix Pharmaceuticals (NASDAQ:SLXP) last announced its earnings results on Thursday, May 8th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.14. The company had revenue of $384.00 million for the quarter, compared to the consensus estimate of $372.91 million. During the same quarter in the previous year, the company posted $0.63 earnings per share. The company’s revenue for the quarter was up 89.7% on a year-over-year basis. Analysts expect that Salix Pharmaceuticals will post $6.52 EPS for the current fiscal year.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.